Drug Trial Radar · NCT00624780
Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder
Last checked: Nov 19, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
615
Actual
Start
May 2009
Primary completion
Apr 2012
Study completion Apr 2012
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 27, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety and efficacy in patients with generalized anxiety disorder after short- (3 months) and long-term (6 months) use of Pregabalin (Lyrica).
Conditions
- Generalized Anxiety Disorder
Interventions
PregabalinDrug
Pregabalin 150-300 mg given twice a day
LorazepamDrug
Lorazepam 3-4 mg given twice a day
PregabalinDrug
Pregabalin 450-600 mg given twice a day
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
- Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
- Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
- Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
- Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
- Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
- Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
- Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Locations
57 sites in 16 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Buenos Aires, Argentina
Pfizer Investigational Site
Buenos Aires, Argentina
Pfizer Investigational Site
Buenos Aires, Argentina
Pfizer Investigational Site
La Plata, Buenos Aires, Argentina
Pfizer Investigational Site
Lanus, Prov. de Buenos Aires, Argentina
Pfizer Investigational Site
Vienna, Austria
Pfizer Investigational Site
Vienna, Austria
Pfizer Investigational Site
San José, Costa Rica
Pfizer Investigational Site
San José, Costa Rica
Pfizer Investigational Site
Rijeka, Croatia
Pfizer Investigational Site
Split, Croatia
Pfizer Investigational Site
Zagreb, Croatia
Pfizer Investigational Site
Brno, Czechia
Pfizer Investigational Site
České Budějovice, Czechia
Pfizer Investigational Site
Litoměřice, Czechia
Pfizer Investigational Site
Lnáře, Czechia
Pfizer Investigational Site
Mělník, Czechia
Pfizer Investigational Site
Prague, Czechia
Pfizer Investigational Site
Prague, Czechia
Pfizer Investigational Site
Praha 10- Strasnice, Czechia
Pfizer Investigational Site
Strakonice, Czechia
Pfizer Investigational Site
Espoo, Finland
Pfizer Investigational Site
HUS, Finland
Pfizer Investigational Site
Joensuu, Finland
Pfizer Investigational Site
Kuopio, Finland
Pfizer Investigational Site
Seinäjoki, Finland
Pfizer Investigational Site
Turku, Finland
Pfizer Investigational Site
Athens, Greece
Pfizer Investigational Site
Ellisbridge, Ahmedabad, India
Pfizer Investigational Site
Tirupati, Andhra Pradesh, India
Pfizer Investigational Site
Mangalore, Karnataka, India
Pfizer Investigational Site
Pune, Maharashtra, India
Pfizer Investigational Site
Chennai, Tamil Nadu, India
Pfizer Investigational Site
Surabaya, Indonesia
Pfizer Investigational Site
Denpasar, Bali, Indonesia
Pfizer Investigational Site
Jakarta, Jakarta Selatan, Indonesia
Pfizer Investigational Site
Jakarta Selatan, Jakarta Special Capital Region, Indonesia
Pfizer Investigational Site
Kaunas, Lithuania
Pfizer Investigational Site
Kaunas, Lithuania
Pfizer Investigational Site
Klaipėda, Lithuania
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.